European Patent Office

T 1760/11 ((-)-Omeprazole Mg/ASTRAZENECA) vom 13.11.2012

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2012:T176011.20121113
Datum der Entscheidung
13. November 2012
Aktenzeichen
T 1760/11
Antrag auf Überprüfung von
-
Anmeldenummer
00108480.5
Verfahrenssprache
Englisch
Verteilung
An die Kammervorsitzenden verteilt (C)
Amtsblattfassungen
Keine AB-Links gefunden
Weitere Entscheidungen für diese Akte
T 1760/11 (-)--'Omeprazole Mg/ASTRAZENECA 2012-11-16
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
Magnesium salt of the (-)-enantiomer of omeprazole and its use
Name des Antragstellers
AstraZeneca AB
Name des Einsprechenden
Hexal AG
Teva Pharmaceutical Industries
Mepha AG
STADA Arzneimittel AG
Pinewood Laboratories Limited
ETHYPHARM
Actavis Group hf.
Lupin Limited
Zentiva a.s.
Generics [UK] Limited
Ratiopharm GmbH
lA Pharma GmbH
Hexal Pharma GmbH
Hörnchen, Ulrich, Dr.
Kammer
3.3.01
Leitsatz
-
Schlagwörter
Admissibility of first partiality objection (yes), second (no)
Res judicata (no)
Main request, added matter (yes)
Auxiliary request 1, allowable
Added matter (no)
Sufficiency (yes), starting material retrievable from Chemical Abstracts
Novelty (yes), specific salt
Inventive step (yes), post-published evidence (yes), unexpected advantage
Referral to the Enlarged Board of Appeal (no)
Objection under Rule 106 EPC dismissed
Orientierungssatz
-

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the department of first instance with the order to maintain the patent with the following claims and a description to be adapted if necessary:

Claim(s): No. 1 to 13 of the auxiliary request 1 filed with the letter dated 6 April 2011 and received on 7 April 2011.

3. The request for referral to the Enlarged Board of Appeal of 15 November 2012 is rejected.

4. The objection of 16 November 2012 under Article 24(3) EPC is rejected as inadmissible.

5. The objection of 15 November 2012 under Rule 106 EPC is dismissed.